Original article
Mineral homeostasis and bone mass in children treated for acute lymphoblastic leukemia

https://doi.org/10.1016/S0022-3476(89)80138-6Get rights and content

Clinical observations of bone pain, abnormal gait, and unusual fractures during remission of leukemia led us to assess mineral status in a cohort of 16 children with acute lymphoblastic leukemia treated with intensive chemotherapy. During maintenance and 6 months after the completion of therapy, blood and urine were analyzed for calcium and magnesium and blood for osteocalcin, vitamin D, and parathyroid hormone. Bone mineral content and bone width of the distal one third of the radius of the nondominant arm was measured by single-photon absorptiometry. During therapy, mild ionic hypocalcemia (<1.19 mmol/L) and hypomagnesemia (<0.77 mmol/L) were demonstrated in 9 and 8 of 16 children, respectively; hypercalciuria (8/16) and hypomagnesiuria (12/16) were also observed. Plasma osteocalcin values correlated with plasma magnesium levels (r=0.54; p<0.05). Oral magnesium supplements normalized plasma magnesium, calcium, and osteocalcin levels, all of which were normal at the postchemotherapy study. Plasma 1,25-dihydroxyvitamin D levels were nondetectable (<8 ng/ml) in 12 of 13 patients receiving therapy and in 7 of 14 patients not receiving therapy; alkaline phosphatase activity increased significantly after therapy (179±86 to 340±101 units/L), and parathyroid hormone levels were normal in both studies. Bone mineral content/bone width ratio was <1 SD below the mean for age- and sex-related population standards in 70% of patients. These data indicate that alterations in magnesium, calcium, and vitamin D metabolism in children treated for acute lymphoblastic leukemia may be instrumental in inducing or sustaining altered bone turnover during chemotherapy.

References (52)

  • EpsteinBS

    Vertebral changes in childhood leukemia

    Radiology

    (1957)
  • CohnSL et al.

    The spectrum of metabolic bone disease in lymphoblastic leukemia

    Cancer

    (1987)
  • NewmanAS et al.

    Vertebral compression in childhood leukemia

    Am J Dis Child

    (1973)
  • SamudaGM et al.

    Back pain and vertebral compression: an uncommon presentation of childhood acute lymphoblastic leukemia

    J Pediatr Orthop

    (1987)
  • MaseraG et al.

    Prognostic significance of radiological bone involvement in childhood acute lymphocytic leukemia

    Arch Dis Child

    (1977)
  • SallanSE et al.

    Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia

    Cancer Res

    (1983)
  • ClavellLA et al.

    Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia

    N Engl J Med

    (1986)
  • Health and Welfare of Canada

    Condensed Canadian nutrient file

    (1984)
  • SabryJH et al.

    Nutrient intake system (user's guide for the program R8174 (intake 82)

    (1982)
  • Department of National Health and Welfare

    Recommended nutrient intakes for Canadians

    (1983)
  • TannerJM et al.
  • MacIntyreI

    Flame photometry

    Adv Clin Chem

    (1961)
  • BowersGN et al.

    Measurement of total alkaline phosphatase activity in human serum

    Clin Chem

    (1975)
  • FrayerLJ et al.

    Radioimmunoassay of 1,25-dihydroxyvitamin D2: studies on the metabolism of vitamin D2 in man

    Clin Endocrinol (Oxf)

    (1983)
  • GundbergCM et al.

    Osteocalcin: isolation, characterization and detection

    Methods Enzymol

    (1972)
  • CameronJR et al.

    Precision and accuracy of bone mineral determination by direct photon absorptiometry

    Invest Radiol

    (1968)
  • Cited by (88)

    • Systematic review and meta-analysis: Prevalence and possible causes of vitamin D deficiency and insufficiency in pediatric cancer patients

      2016, Clinical Nutrition
      Citation Excerpt :

      PTH measured alongside vitamin D is considered a more sensitive physiological measure of vitamin D status in the healthy population [6]; therefore this was also assessed. Twelve out of 19 studies [22–27,30–33,35,38] investigated plasma PTH levels as well as 25(OH)D or 1,25(OH)D (Table 1). However, only 5 studies reported plasma PTH in relation to either 25(OH)D or 1,25(OH)D with very heterogeneous findings: (i) Bilariki et al. (2010) [24] reported hyperparathyroidism in half of patients (n = 15) who were 25(OH)D deficient (n = 32); (ii) Atkinson et al. (1989) [31] reported normal plasma PTH and 25(OH)D in all ALL patients; (iii) Halton et al. (1996) [27] stated that 9 children with low 1,25(OH)D had also developed hyperparathyroidism; (iv) Schepper et al. (1994) [35] found normal plasma 1,25(OH)D levels, however 15% (2/13) of these had hyperparathyroidism and 8% (1/13) hypoparathyroidism; (v) Finally, Sinha et al. (2011) [38] did not establish any significant associations between plasma 25(OH)D and PTH levels in pediatric cancer patients (r = 0.07; p = 0.65); but this association was significant in the control group (r = −0.42; p < 0.01).

    • Bone health in patients with brain tumors

      2007, Surgical Neurology
      Citation Excerpt :

      To our knowledge, no data have been published about bone loss related to chemotherapic drugs commonly used in brain tumor treatment such as nitrosoureas (BCNU, CCNU) or temozolomide. There are reports of increased incidence of fractures among children after use of MTX for leukemia, although many of these children probably received GCs as well [3]. The mechanism of action of MTX on bone at a cellular level remains unclear, although MTX affects bone cell mechanotransduction by interfering with integrin-mediated signaling [25].

    • Bone morbidity in pediatric acute lymphoblastic leukemia

      2020, Annals of Pediatric Endocrinology and Metabolism
    View all citing articles on Scopus
    1

    Dr Atkinson is a Career Scientist of the Ministry of Health of Ontario

    2

    Dr. Fraher is a National Institute of Nutrition (Canada) University Scholar.

    View full text